Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993.
Incyte has one drug, Jakafi, which has been approved by the U.S. Food and Drug Administration(FDA) and has been prescribed to several thousand patients in the United States.[3]
As of 2014 the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[4][5] It gained EU approval in February 2017.[6] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[7][8]
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck’s pembrolizumab (Keytruda) and Bristol Myers Squibb’s nivolumab (Opdivo).[9][10]
Novartis acquired Incyte’s c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma.[11]
In an exclusive interview, Stephen Ubl, President and CEO of the Pharmaceutical Researchers and Manufacturers of America (PhRMA), the association representing the leading innovative biopharmaceutical companies in the USA, discusses…
In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs;…
Rolando Pablos, Secretary of State of Texas, discusses Texas’s unique business-friendly environment, the significance of the life sciences sector to the state’s economy (which would be the tenth largest in…
Benjamin Wu of the Maryland Department of Commerce discusses the importance of the life sciences to the state, how Maryland is performing in terms of technology transfer, and its potential…
Helen Stimson, president of the Delaware BioScience Association, discusses Delaware’s attractive cost of living, legal system, interconnectivity, as well as the vital role that the life sciences play within the…
Speaking exclusively to PharmaBoardroom at the 2017 BIO Convention in San Diego, former FDA Commissioner Andrew von Eschenbach lifts the lid on the ‘FDA Beyond Our Borders’ project that he…
While pledging to lower drug prices has proved popular, the Trump administration’s proposed FDA reform has been getting some pharmaceutical executives worried. In a meeting with Big Pharma CEOs at…
Take our poll on Donald Trump and Pharma at the bottom of the article Speaking at a White House meeting with senior pharmaceutical executives, US President Donald Trump told drug companies…
In part II of an exclusive interview at the eyeforpharma Barcelona Summit 2016, IMS Health’s Chief Digital Officer Richie Etwaru lifts the lid on the concept of Orchestrated Customer Engagement (OCE) and…
The pharmaceutical industry in Asia is undergoing a period of specialization with R&D booming in places like Australia, Singapore and South Korea and manufacturing in places like China, India and…
See our Cookie Privacy Policy Here
